Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Pasithea Therapeutics Corp. announced that Lawrence Steinman, Chairman, will deliver a significant lecture at the ACTRIMS Forum in San Diego on February 23, 2023. The event, themed “MS: Going Viral,” focuses on the role of the Epstein-Barr virus in Multiple Sclerosis (MS), which relates to the Company's PAS-002 drug discovery program. PAS-002 aims to create an engineered DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS. MS affects 2.8 million people globally, with relapsing remitting MS being the most common type. Steinman's research was recognized as a runner-up for Science Magazine’s 2022 Breakthrough of the Year.
- Pasithea's PAS-002 program targets GlialCAM, offering a novel approach to treat MS.
- Lawrence Steinman's upcoming lecture highlights significant research on Epstein-Barr virus and MS, increasing visibility for Pasithea.
- None.
Event theme, “MS: Going Viral” touches on the role of viruses in MS, particularly Epstein-Barr, a topic related to Company’s PAS-002 drug discovery program
PALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will deliver the Dr. Kenneth P. Johnson lecture at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) on February 23 in San Diego, California.
The ACTRIMS Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS. The lecture allows attendees an opportunity to hear from a prestigious researcher selected for their contributions to multiple sclerosis. Prof. Steinman’s research on the link between Epstein-Barr virus and multiple sclerosis was a runner-up for Science Magazine’s 2022 Breakthrough of the Year.
About PAS-002
The Company’s PAS-002 discovery program aims to develop a proprietary engineered DNA plasmid vaccine to tolerize the immune system to GlialCAM for the treatment of multiple sclerosis. GlialCAM, a CNS protein, found in the brain’s white matter is attacked in MS. GlialCAM shares a component of its structure that mimics an identical component of Epstein-Barr virus nuclear antigen 1 (EBNA-1), which plays a critical role in triggering MS.
About Multiple Sclerosis
Multiple sclerosis (“MS”) is a chronic and potentially disabling autoimmune disease, and the most common neurodegenerative disease of the central nervous system in young adults. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, with the immune system attacking the myelin sheath that normally protects nerve fibers in the brain, spinal cord, and optic nerve. There are now 2.8 million people worldwide who have MS, and every five minutes, someone, somewhere in the world is diagnosed with this disorder. While there is no way to predict with any certainty how an individual’s disease will progress, four basic MS disease courses (also called types or phenotypes) have been defined: clinically isolated syndrome, relapsing remitting, secondary progressive and primary progressive. The most common affecting around 85 per cent of everyone diagnosed with MS is relapsing remitting MS (RRMS). It means that symptoms appear (a relapse), and then fade away, either partially or completely (remitting).
About Pasithea Therapeutics Corp.
Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders. We leverage our expertise in the fields of neuroscience, medicinal chemistry, and translational medicine to develop new molecular entities that target the pathophysiology underlying such diseases with the goal of bringing life-changing therapies to patients.
Forward Looking Statements
This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
Email: tiago@pasithea.com
FAQ
What is the theme of the upcoming ACTRIMS Forum lecture by Pasithea's Chairman?
What is the PAS-002 drug discovery program?
How common is Multiple Sclerosis globally?
Who is delivering the lecture at ACTRIMS Forum on February 23, 2023?
What recognition did Lawrence Steinman's research on MS receive?
